Fortfahren mit
O7125
L-Ornithin -L-aspartat (Salz)
≥98% (TLC)
Synonym(e):
(S)-2,5-Diaminopentanoic acid L-aspartate salt
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 25 g | Ab HEUTE lieferbarvonSchnelldorf | 154,00 € |
Über diesen Artikel
Empirische Formel (Hill-System):
C9H19N3O6
CAS-Nummer:
Molekulargewicht:
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenProduktname
L-Ornithin -L-aspartat (Salz), powder
assay
≥98% (TLC)
Quality Level
form
powder
color
white to off-white
storage temp.
2-8°C
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
Biochem/physiol Actions
L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.
Other Notes
Product of arginine degradation by arginase
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (TLC) | assay ≥99% | assay ≥99% | assay ≥99.0% (AT) |
| storage temp. 2-8°C | storage temp. - | storage temp. - | storage temp. - |
| color white to off-white | color white | color white | color - |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 100 |
Lagerklasse
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Global Trade Item Number
| SKU | GTIN |
|---|---|
| O7125-25G | 04061834248392 |
| O7125-100G | 04061834248385 |